CA
LKFT

Crewe Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Crewe Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46
Closed -$1.5K – 1084
2025
Q4 		$1.5K Hold
46
– – ﹤0.01% 929
2025
Q3 		$1.59K Buy
+46
New +$1.47K ﹤0.01% 873

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Crewe Advisors's LKFT Position: Q1 2026 in Review

Crewe Advisors sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2026, closing a stake of 46 shares — an estimated $1.5K sold.

Crewe Advisors first reported a position in LKFT in Q3 2025 and held it in 2 quarters. The position peaked at $1.59K in Q3 2025. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • Crewe Advisors reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2026 after selling out during the quarter.
  • Crewe Advisors sold 46 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $1.5K.
  • Crewe Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2025 and held it in 2 quarters.
  • Crewe Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $1.59K in Q3 2025.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Crewe Advisors's 13F filing for Q1 2026, filed 7 May 2026.